Searchable abstracts of presentations at key conferences in endocrinology

ea0089b2 | Basic Science | NANETS2022

Multiple Layers of Epigenetic Regulation Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine Tumors

Madigan James P. , Sharma Rupali , Mondell Ethan , Sadowski Samira M.

Background: Pancreatic neuroendocrine tumors (P-NETs) are a rare cancer with increasing incidences worldwide. Low-grade P-NETs are unique in that they express high levels of Somatostatin Receptor Type 2 (SSTR2), which represents a target for both tumor imaging and therapeutics. P-NET grade inversely correlates with SSTR2 tumor staining, and higher tumor grade is associated with poor patient prognosis. Unfortunately, application of SSTR2-targeted treatment options is currently ...

ea0089b1 | Basic Science | NANETS2022

Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors

Rajhans Shreya , Mondell Ethan , Madigan James , Truongvo Nhi , Wang Li , Kelly Michael , Sadowski Samira M. , Efsun Arda H.

Background: Pancreatic neuroendocrine tumors (PNETs) are a rare, understudied form of cancer with few curative options, and their occurrence is rising. With approximately 4,000 new cases diagnosed per year in the US, and a 5-year relative survival rate of 54%, itÂ’s imperative to understand the molecular mechanisms governing PNET carcinogenesis. To date, most studies used whole-tumor sequencing to characterize PNETs, which hampers the discovery of their microenvironment, c...

ea0098b27 | Basic Science | NANETS2023

Development of GEP-NEN patient derived organoids for therapy screening

Forsythe Steven D. , Madigan James P. , Andrews Stephen , del Rivero Jaydira , Hernandez Jonathan M. , Nilubol Naris , Sadowski Samira M.

Background: Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) are a rare subset of cancers which nevertheless are a rising health burden. Development of new therapies suffers from several bottlenecks, including low patient accrual and poor understanding of tumor characteristics. Patient tumor organoids (PTOs) are a novel model capable of improving screening of patient tissue in an accurate, standardized, and high-throughput capacity. In this study, we utilized patient...